Home | About IJMPO | Editorial board | Search | Ahead of print | Current Issue | Archives | Instructions | Subscribe | Advertise | Contact us |  Reader Login
Indian Journal of Medical and Paediatric Oncology
Search Article 
  
Advanced search 
 
Export selected to
Endnote
Reference Manager
Procite
Medlars Format
RefWorks Format
BibTex Format
  Access statistics : Table of Contents
   2003| January-March  | Volume 24 | Issue 1  
    Online since May 30, 2009

 
 
  Archives   Previous Issue   Next Issue   Most popular articles   Most cited articles
 
Hide all abstracts  Show selected abstracts  Export selected to
  Viewed PDF Cited
Adenocarcinoma sigmoid colon in a 11 year old male child : a case report
PK Jain, K.S Budhwani, R.K. Ghritlaharey
January-March 2003, 24(1):37-39
Colorectal cancer is rare in children, with an incidence of 1.3 to 2/million in the U.S.A. Presentation is usually vague & the diagnosis is delayed for few weeks to several months. The prognosis of colorectal carcinoma in children is extremely poor as compared to adults. We describe here an 11 years old male child who presented with features of intestinal obstruction. On exploration, there was a stricture at sigmoid colon, extensive intra-abdominal tumour & dense adhesions of tumour to left side of iliac vessels. Colo-colic anastomosis was done to bye pass the obstruction. One & half months after initial laparotomy, he came with intestinal obstruction again. On second exploration, adbomen was found to be plastered with dense adhesions, so loop of terminal ileum was brought out as loop ileostomy. The histopathological report was mucinous adenocarcinoma of colon with metastasis in omentum & mesenteric lymph nodes. Response to chemotherapy was poor & finally he died of progressive disease, eight months after diagnosis. The intention of presentation here is its rarity in children.
[ABSTRACT]   Full text not available   
  727 0 -
Waldenstrom's Macroglobulinemia : report of 8 cases
K Ganessan, L Kumar, A Sharma, V Kochupillai
January-March 2003, 24(1):9-12
Background: Waldenstrom's Macroglobulinemia (WM) is a lymphoproliferative disorder characterized by neoplastic B-lymphocytes infiltrating the bone marrow and other lymphoid organs with the production of monoclonal IgM protein. Patients and Methods: In this report, we review the cases of WM seen at IRCH, AIIMS, New Delhi, in the last 5 years. Criteria for diagnosis included serum monoclonal IgM protein along with 20 percent bone marrow lymphocytes. Eight cases were included in the study with a median age of 59.5 years at diagnosis and male/female ratio 7:1. Two patients were asymptomatic at diagnosis. The common clinical features at presentation were fatigue (100 percent), malaise (100 percent), bleeding tendencies (66.6 percent), symptoms suggestive of hyperviscosity (33.3 percent). Anemia was seen in 75 percent cases, hepatomegaly in 37.5 percent cases, splenomegaly in 25 percent cases, lymphadenopathy in 12.5 percent cases. None had peripheral neuropathy. Laboratory investigations revealed a mean Hb8.1g/dl, mean TLC 6.2' 10/1, mean platelet count 1.09 ' 10/1 and mean ESR 100.6 mm/hr. 75 percent cases had diffuse bone marrow involvement by lympho/lymphoplasmacytoid cells. The mean serum M spike concentration was 3.18g/dl and all the patients had IgM kappa subtype. As initial therapy, 5 patients received Chlorambucil/Prednisolone, 1 patient received VAD chemotherapy and the other 2 asymptomatic patients were observed without any therapy. None had complete response. 2 had partial response while 3 had minimal response. One of the asymptomatic case progressed after a period of 18 months of observation. 7 out of 8 cases were alive at the time last follow up. The overall median survival was 19.5 months and progression free survival was 16.3 months. Conclusion: Though a rare disorder, high clinical suspicion is required to diagnose WM. Therapy with Chlorambucil/Prednisolone provides adequate disease control.
[ABSTRACT]   Full text not available   
  710 0 -
GLIVEC and GIST : paradigm shift in cancer therapy
J Wadhwa
January-March 2003, 24(1):22-23
EFFICACY AND SAFETY OF IMATINIB MESYLATE IN ADVANCED GASTROINTESTINAL STROMAL TUMORS DEMETRI GD, ET AL. N ENGL J MED 2002; 347 (7): 472-80. IMATINIB MESYLATE-A NEW ORAL TARGETED THERAPY. SAVAGE DG. ET AL. N ENGL J MED 2002; 346 (9): 683-693.
[ABSTRACT]   Full text not available   
  696 0 -
Clinical profile of non-small cell lung cancer at a teaching Hospital in south India
K Sambasivaiah, MK Reddy, M Venkaramanappa, B Phanindra, KVS Sarma, NK Venugopal
January-March 2003, 24(1):4-8
Background: Non-small cell lung carcinoma (NSCLC) is the leading cause of cancer mortality in the world. Surgery is not an option for two thirds of patients, because of advanced disease at the time of diagnosis. Therefore, most patients with NSCLC receive palliative treatment by chemotherapy or radiotherapy or both. Chemotherapy has been shown to improve survival and quality of life. The median survival for advanced NSCLC ranges from 6-10 months. Patients and Methods : To study the epidemiological, clinical and survival patterns., we conducted a retrospective analysis of 54 patients with NSCLC treated at this center between 6th July 2002 to 1st May, 2002. Patients age ranged from 26 to 85 years (median-60 years), 43 were males and 11 females. UICC staging revealed : stage I-4, II-2, III-42 and stage IV in 4 patients. Histological subtypes were squamous-37, adenocarcinoma-11, large cell-3 and poorly differentiated-3. Curative surgery was performed for five patients. Thirty one patients received induction chemotherapy with MIC regimen (cisplatinum 100mg/m2, Ifosfamide 3gr/m2 and Mitomycin 6mg/m2) and one patient received EP regimen. Out of these, twenty two patients received three or more cycles. Four patients received oral etoposide and one patient opted for alternate medicines, three patients died of progressive disease and eleven patients did not receive any treatment. Two patients received Radiotherapy, after completion of the chemotherapy. Both patients died while on radiotherapy. Results : 19 of 32 (72 percent) patients responded to chemotherapy; complete response-6(27 percent), partial response-13 (45 percent). The median survival for patients with advanced disease is 9.9 months (95 percent CI 6.3-13.4). Three patients were post surgery and were not offered adjuvant chemotherapy. Fatigue, anemia and reversible alopecia are the common toxicities encountered in this study. Raised ESR and LDH are associated with poor out come (P0.05). The number of chemotherapy cycles (3) are associated with better survival than the fewer number of chemotherapy. Conclusions: Squamous cell carcinoma is the commonest histological subtype. Adenocarcinoma is more common among non smokers and women. Eighty five percent of patients present with inoperable, advanced disease. Cisplatin based combination chemotherapy results in over all response rate of 75 percent and a medium survival of 9.9 months among advanced NSCLC. Elevated ESR and LDH are associated with poor outcome.
[ABSTRACT]   Full text not available   
  612 0 -
Infantile hepatic hemangioendothelioma : a case report
SR Rane, AN Kavatkar, I.N Bagwan, V.V Holla
January-March 2003, 24(1):35-36
Infantile hepatic hemangioendothelioma is a rare benign vascular tumor that presents most commonly before the age of six months as an abdominal mass with or without congestive cardiac failure. Our patient was a two month old child with this tumor.
[ABSTRACT]   Full text not available   
  595 0 -
Current Status of high dose chemotherapy and hemotopoietic stem cell transplantations in breast cancer.
A Sharma, V Raina
January-March 2003, 24(1):13-18
Breast cancer is one of the most common cancer in females. A large number of patients succumb to this disease each year. One of the various novel approaches developed, is high dose chemotherapy (HDCT) and hematopoietic stem cell transplantation (HSCT). The fact that breast cancer is a chemosenstitive disease is the main principle based on which significant number of patient both in metastatic and adjuvant setting are offered HDCT and HSCT. However, the available literature which is reviewed here doesn't conclusively prove that HDCT and HSCT is superior to standard dose chemotherapy.
[ABSTRACT]   Full text not available   
  588 0 -
Systemic therapy for breast cancer : the action is now in the field of hormonal therapy
A Goel, D Singh, M Nandy
January-March 2003, 24(1):19-21
DOUBLE BLIND, RANDOMIZED TRIAL COMPARING THE EFFICACY AND TOLERABILITY OF FULVESTRANT VERSUS ANASTRAZOLE IN POSTMENOPAUSAL WOMEN WITH ADVANCED BREAST CANCER PROGRESSING ON PRIOR ENDOCRINE THERAPY: RESULTS OF A NORTH AMERICAN TRIAL. J. CLIN ONCOL, 2002; 20:3386-95
[ABSTRACT]   Full text not available   
  569 0 -
Nutritional Support for children with cancer
T Seth, K Ganessan
January-March 2003, 24(1):30-34
Full text not available   
  329 0 -
Chronic Myeloid Leukemia
TK Saikia
January-March 2003, 24(1):24-29
Full text not available   
  295 0 -
  Feedback 
  Subscribe